Next Article in Journal
Influence of the RelA Activity on E. coli Metabolism by Metabolite Profiling of Glucose-Limited Chemostat Cultures
Next Article in Special Issue
Computational Methods for Metabolomic Data Analysis of Ion Mobility Spectrometry Data—Reviewing the State of the Art
Previous Article in Journal
From Cycling Between Coupled Reactions to the Cross-Bridge Cycle: Mechanical Power Output as an Integral Part of Energy Metabolism
Previous Article in Special Issue
What mRNA Abundances Can Tell us about Metabolism
Article

Differentiating Hepatocellular Carcinoma from Hepatitis C Using Metabolite Profiling

1
Department of Chemistry, Purdue University, 560 Oval Dr., West Lafayette, IN 47907, USA
2
Department of Surgery, IU School of Medicine, 550 University Blvd., UH 4601, Indianapolis, IN 46202, USA
*
Authors to whom correspondence should be addressed.
Metabolites 2012, 2(4), 701-716; https://doi.org/10.3390/metabo2040701
Received: 1 August 2012 / Revised: 12 September 2012 / Accepted: 25 September 2012 / Published: 10 October 2012
(This article belongs to the Special Issue Metabolism and Systems Biology)
Hepatocellular carcinoma (HCC) accounts for most liver cancer cases worldwide. Contraction of the hepatitis C virus (HCV) is considered a major risk factor for liver cancer. In order to identify the risk of cancer, metabolic profiling of serum samples from patients with HCC (n=40) and HCV (n=22) was performed by 1H nuclear magnetic resonance spectroscopy. Multivariate statistical analysis showed a distinct separation of the two patient cohorts, indicating a distinct metabolic difference between HCC and HCV patient groups based on signals from lipids and other individual metabolites. Univariate analysis showed that three metabolites (choline, valine and creatinine) were significantly altered in HCC. A PLS-DA model based on these three metabolites showed a sensitivity of 80%, specificity of 71% and an area under the receiver operating curve of 0.83, outperforming the clinical marker alpha-fetoprotein (AFP). The robustness of the model was tested using Monte-Carlo cross validation (MCCV). This study showed that metabolite profiling could provide an alternative approach for HCC screening in HCV patients, many of whom have high risk for developing liver cancer. View Full-Text
Keywords: hepatocellular carcinoma; heptatitis C; metabolomics; NMR hepatocellular carcinoma; heptatitis C; metabolomics; NMR
Show Figures

Figure 1

MDPI and ACS Style

Wei, S.; Suryani, Y.; Gowda, G.A.N.; Skill, N.; Maluccio, M.; Raftery, D. Differentiating Hepatocellular Carcinoma from Hepatitis C Using Metabolite Profiling. Metabolites 2012, 2, 701-716. https://doi.org/10.3390/metabo2040701

AMA Style

Wei S, Suryani Y, Gowda GAN, Skill N, Maluccio M, Raftery D. Differentiating Hepatocellular Carcinoma from Hepatitis C Using Metabolite Profiling. Metabolites. 2012; 2(4):701-716. https://doi.org/10.3390/metabo2040701

Chicago/Turabian Style

Wei, Siwei, Yuliana Suryani, G. A. Nagana Gowda, Nicholas Skill, Mary Maluccio, and Daniel Raftery. 2012. "Differentiating Hepatocellular Carcinoma from Hepatitis C Using Metabolite Profiling" Metabolites 2, no. 4: 701-716. https://doi.org/10.3390/metabo2040701

Find Other Styles

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Back to TopTop